-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

902.O2.6 902. Health Services Research—Malignant Conditions (Lymphoid Disease) I

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological, multiple myeloma, Adult, ALL, AML, CRS, Leukemia, survivorship, Diseases, Lymphoma (any), neurotoxicity, Non-Biological, CAR-Ts, Hodgkin Lymphoma, Therapies, Combinations, Elderly, Non-Hodgkin Lymphoma, Adverse Events, chemotherapy, Pediatric, Young Adult, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Myeloid Malignancies, Clinically relevant, Quality Improvement
Saturday, December 5, 2020: 2:00 PM-3:30 PM
Moderators:
Allison A. King, MD, MPH, PhD, Washington University in St. Louis, School of Medicine and Brandon Blue, MD, Moffitt Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
2:00 PM
306
The Impact of Different Ethical Allocation Strategies on Survival during Vincristine Shortages

Andrew Hantel, MD1, Michael McManus, MD, MPH2* and Gregory A. Abel, MD, MPH1

1Dana-Farber Cancer Institute, Boston, MA
2Boston Children's Hospital, Boston, MA
2:15 PM
307
Hospitalization Patterns and Medicare Spending for Non-Malignant Morbidity Among Older Survivors of Non-Hodgkin Lymphoma (NHL)

Kelly Kenzik, PhD1*, Gaurav Goyal, MD2, Amitkumar Mehta, MD3 and Smita Bhatia, MD, MPH1

1Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL
2University of Alabama at Birmingham, Birmingham, AL
3University of Alabama School of Medicine, Birmingham, AL
2:30 PM
308
Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Amy J. Davidoff, PhD1,2*, Jessica B Long, MPH3*, Natalia Neparidze, MD4, Jan Philipp Bewersdorf, MD5*, Rory M. Shallis, MD6, Nikolai A. Podoltsev, MD, PhD7, Rong Wang, PhD8*, Steven D. Gore, MD9, Amer M. Zeidan, MBBS, MHS10 and Scott F. Huntington, MD, MPH11

1Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT
2Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT
3Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University School of Medicine, New Haven, CT
4Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
5Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
6Department of Internal Medicine, School of Medicine and Yale Cancer Center, Yale University, New Haven, CT
7Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT
8Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT
9NIH/NCI Cancer Therapy Evaluation Program, Rockville, MD
10Yale University School of Medicine and Yale Cancer Center, New Haven, CT
11Hematology, Yale University School of Medicine, New Haven, CT
2:45 PM
309
Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study

Gwynivere A Davies, MD MPH1, John E. Orav, PhD2* and Kristen Brantley, MPH3*

1McMaster University, Department of Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada
2Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA
3Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
3:00 PM
310
Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California

Lena E. Winestone, MD, MSHP1,2, Qian Li, MS3*, Lori Muffly, MD, MS4, Kelly D Getz5*, Elysia Alvarez, MD, MPH3*, Ted Wun, MD3 and Theresa Keegan, PhD, MS3

1Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
2Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, Benioff Children's Hospital, San Francisco, CA
3Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA
4Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA
5Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
3:15 PM
311
Health Care Utilization and End of Life (EOL) Outcomes in Patients Receiving CAR T-Cell Therapy

Patrick Connor Johnson, MD1, Matthew J Frigault, MD, MSc2, Alisha Yi1*, Mitchell W Lavoie, BS1*, Caron Jacobson, MD, MMSc3 and Areej El-Jawahri, MD4

1Massachusetts General Hospital, Boston, MA
2Blood and Marrow Transplant Program, Massachusetts General Hospital / Harvard Medical School, Dorchester, MA
3Dana Faber Cancer Institute, Harvard Medical School, Boston, MA
4Massachusetts General Hospital / Harvard Medical School, Allston, MA
See more of: Oral and Poster Abstracts
<< Previous Session | Next Session >>
*signifies non-member of ASH